[Home] [Reports] [Startups] [ONLINE STORE] [site map]

Methodology

Order Report via our online store
 

The report below has been updated in the 2010 report on

"Products, Technologies, Markets and Opportunities

in Diabetes Management Worldwide, 2009-2018"

Click for details

 

Products, Technologies, Markets and Opportunities in

 Diabetes Management Worldwide, 2005-2015

Report D500


·
276 pages   · 82 Exhibits   · 96 Company Profiles   · February 2006   · Report #D500
 

Worldwide report on products, trends, competitors and markets for diabetes management.

This report details the worldwide incidence and prevalence by country/region of Type 1 and Type 2 diabetes and details the current and projected market for diagnostic and therapeutic products in the management of diabetes, including anti-diabetic drugs, alternative insulin types, blood glucose monitoring (including continuous monitoring devices), insulin pumps, and other established and emerging products in diabetes management.  The report provides an emphasis of detail on the status of development of novel products including noninvasive monitoring, oral/inhaled/other insulin delivery. The report details the clinical and technology developments underlying this huge and evolving worldwide market, with data on products in development and on the market; market size and forecast; competitor market shares; competitor profiles; and market opportunity.  Separate size, growth and competitor share data are presented for the U.S., individual western European countries (Belgium, Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom), and Japan.  The report profiles active companies including detailed profile information on major competitors, brief profiles of companies with less sizeable current or potential positions in the market, plus additional profiles of companies with novel or advanced research activities in the market.

The report establishes the current worldwide market size for major technology segments as a baseline for and projecting growth in the market over a ten-year forecast. The report also assesses and projects the composition of the market as technologies gain or lose relative market performance over this period.

Products & Technologies Covered:

  • Oral hypoglycemic drugs

  • Insulin by type

  • Blood glucose monitors

  • Lancets

  • Blood sampling devices

  • HbA1c testing

  • Insulin pumps

  • Insulin syringes

  • Inhaled insulin

  • Artificial pancreas

  • Pancreatic transplant

  • Islet cell transplants

  • Stem cell

  • Antibody treatment

  • Vaccines

  • Genetic approaches

  • Novel drugs

  • Continuous glucose monitoring

 

Table of Contents

 

EXECUTIVE SUMMARY

Some Diabetes Basics

A Large and Growing Market

A Many-Sided Market

Pharmaceuticals for Diabetes

Insulin

Oral Anti-diabetic Drugs

The Pharmaceutical Diabetes Market

Insulin Administration Devices

Medical Devices for Diabetes

Total Diabetes Market

Regional Segmentation

Market Growth

The Diabetes Industry

Pharmaceutical Companies

Medical Device Companies

Section 1:        ABOUT DIABETES

 

1.1       What is Diabetes?

 

1.2       Blood Sugar Regulation

1.2.1          Insulin

1.3       Main Types of Diabetes

1.3.1          Type 1 Diabetes

1.3.2          Type 2 Diabetes

1.3.3          Gestational Diabetes

1.3.4          Obesity-Related type 2 Diabetes in Children.

1.3.5          Mature-onset Diabetes of the Young (MODY)

1.3.6          Other Diabetic States

1.4       Diagnosis

1.4.1          Glucose Tests

1.4.2          Official Criteria

1.4.3          Differential Diagnosis

1.4.3.1       Type 1 Diabetes

1.4.3.2       Type 2 Diabetes

1.5       Current Treatment

1.5.1          Type 1 Diabetes

1.5.2          Type 2 Diabetes

1.5.3          Diet

1.6       Future Treatment Approaches

 

1.7       Treatment Monitoring

1.7.1          Blood Sugar Control

1.7.2          The Diabetes Control and Complications Trial

1.7.3          Glycated haemoglobin (HbA1c)

1.7.4          Fructosamine

1.8       Incidence and Prevalence of Diabetes (Type 1 & Type 2)

1.8.1          Worldwide

1.8.2          USA

1.8.3          Japan

1.8.4          Europe

1.9       Diabetic Complications

1.9.1          Retinopathy

1.9.2          Neuropathy

1.9.3          Nephropathy

1.10     Metabolic Syndrome

 

Section 2:        Products Used in Diagnosis and Monitoring

 

2.1       Blood Glucose Monitoring Devices:  Suppliers and Products

2.1.1          Lancets

2.1.2          Blood Sampling Devices

2.1.2.1       Bayer Diagnostics

2.1.2.2       Becton Dickinson

2.1.2.3       Cell Robotics

2.1.2.4       LifeScan

2.1.2.5       Roche Diagnostics

2.1.3          Blood Glucose Monitors

2.1.3.1       77 Elektronica Kft

2.1.3.2       Abbott Laboratories

2.1.3.3       Acon Laboratories Inc.

2.1.3.4       Apex Biotechnology Corp.

2.1.3.5       Bayer Corporation

2.1.3.6       Becton Dickinson & Co

2.1.3.7       Belbiosens

2.1.3.8       Cygnus Inc – Animas Corp

2.1.3.9       Diagnostic Devices Inc.

2.1.3.10     Eumed Biotechnology Co. Ltd.

2.1.3.11     HMD Bio Medical

2.1.3.12     Glucoplus Inc

2.1.3.13     HemoCue AB

2.1.3.14     Home Diagnostics Inc

2.1.3.15     Hypoguard

2.1.3.16     LifeScan Inc

2.1.3.17     Medtronic MiniMed

2.1.3.18     Polymer Technology Systems Inc.

2.1.3.19     QuestStar Medical Inc

2.1.3.20     Roche

2.1.3.21     TaiDoc Technology Corporation

2.1.3.22     US Diagnostics Inc.

2.1.4          New Developments in Glucose Testing

2.2       ‘Artificial Pancreas’

2.2.1          Medtronic

2.2.2          Roche

2.2.3          Abbott

2.2.4          Novo Nordisk/LifeScan

2.3       Other Testing Approaches

2.3.1          Hemoglobin A1c

2.3.1.1       Hemoglobin A1c Meters

2.3.1.2       Hemoglobin A1c Kits

2.4       Software Programs for Diabetes Monitoring.

2.4.1          Web Software

2.4.2          Commercial Software

Section 3:        Products Used in Treatment

 

3.1       Insulin

3.1.1          History

3.1.1.1       Bovine and Porcine Insulin

3.1.1.2       Humanized Insulin

3.1.2          Companies Supplying Insulin

3.1.2.1       Eli Lilly

3.1.2.2       Aventis

3.1.2.3       Novo Nordisk

3.1.2.4       Some Other Suppliers

3.1.3          Insulin Delivery

3.1.3.1       Syringes

3.1.4          Insulin Syringe Manufacturers

3.1.4.1       Pens

3.1.4.2       Manufacturers of Insulin Pens

3.1.4.3       Injectors

3.1.4.4       Injector Manufacturers

3.1.5          Inhaled insulin

3.1.6          Pfizer/Sanofi-Aventis/Nektar Therapeutics

3.1.6.1       Lilly/Alkermes

3.1.6.2       Novo Nordisk/Aradigm

3.1.6.3       MannKind

3.1.7          Insulin Pumps

3.1.7.1       What is an Insulin Pump?

3.1.7.2       The Infusion Set

3.1.7.3       Candidates for Pump Therapy

3.1.8          Companies Supplying Insulin Pumps

3.1.8.1       Animas Corporation

3.1.8.2       DANA Diabecare

3.1.8.3       Medtronic MiniMed

3.1.8.4       Nipro Diabetes Systems

3.1.8.5       Roche Disetronic

3.1.8.6       Smiths Medical

3.2       Oral Hypoglycaemic Drugs

3.2.1          Sulfonylureas

3.2.2          Biguanides

3.2.3          Alpha-Glucosidase Inhibitor

3.2.4          Thiazolidinediones

3.2.5          Prandial Glucose Regulators

3.2.6          Incretin Mimetics

3.2.7          Amylin Mimetic

3.2.8          New Products Now in R&D

Section 4:        Novel Approaches to Diabetes Management

 

4.1       Pancreas Transplants

 

4.2       Islet Cell Transplants

4.2.1          Edmonton Protocol

4.2.2          Improving ICT

4.2.3          Living-Donor Islet Cell Transplant

4.3       Stem Cell Developments

4.3.1          ADA Endorsement

4.3.2          Stem Cell Research at EASD 2005

4.3.2.1       Adult Stem Cells

4.4       Antibody Treatment

 

4.5       Vaccines

4.5.1          Diamyd Medical

4.5.2          DeveloGen

4.6       Genetic Approaches

4.6.1          Genetic Testing

4.6.2          Small-interfering RNA (SiRNA)

4.7       Novel Drugs

4.7.1          DDP-IV Inhibitors

4.7.2          Other Drugs

4.7.3          All-in-one Treatment for Type 2 Diabetes?

4.8       Continuous Glucose Monitoring

4.8.1          Electroenzymatic Sensor

4.8.2          Optical Glucose Sensor

4.8.3          Sensor Based on Carbon Nanotubes

 

Section 5:        The Diabetes Market

 

5.1       Global Market

5.1.1          Size

5.1.2          Growth

5.1.3          Regional Segmentation

5.2       Market Analysis by Product Category

5.2.1          Monitoring Products

5.2.1.1       Major Suppliers

5.2.2          Insulins and Insulin Delivery Devices

5.2.2.1       Major Suppliers

5.2.2.1.1          Insulin

5.2.2.1.2          Syringes and Other Insulin Administration Devices

5.2.2.1.3          Insulin Pumps

5.2.3          Oral Antidiabetic Drugs

5.2.3.1       Major Suppliers

5.3       Trends

 

5.4       Main National Markets

5.4.1          Belgium

5.4.2          Denmark

5.4.3          France

5.4.4          Germany

5.4.5          Italy

5.4.6          Japan

5.4.7          Netherlands

5.4.8          Norway

5.4.9          Spain

5.4.10        Sweden

5.4.11        United Kingdom

5.4.12        USA

Section 6:        Company Profiles

 

6.1       Leading Companies

6.1.1          Abbott Laboratories

6.1.1.1       Overview

6.1.1.2       Diabetes Products

6.1.1.3       Pipeline

6.1.1.4       Financials

6.1.2          Bayer

6.1.2.1       Overview

6.1.2.2       Diabetes Products

6.1.2.2.1          Ascensia Blood Glucose Monitoring

6.1.2.3       Financials

6.1.3          Becton Dickinson

6.1.3.1       Overview

6.1.3.2       Diabetes Products

6.1.3.2.1          Insulin Injection Devices

6.1.3.2.2          Glucose monitoring products

6.1.3.3       Financials

6.1.4          Bristol-Myers Squibb

6.1.4.1       Overview

6.1.4.1.1          Problems with Generics

6.1.4.2       Diabetes Products

6.1.4.3       Financials

6.1.5          Eli Lilly

6.1.5.1       Overview

6.1.5.2       Diabetes Products

6.1.5.3       Financials

6.1.5.4       Pipeline

6.1.6          Glaxo SmithKline

6.1.6.1       Overview

6.1.6.2       Diabetes products

6.1.6.3       Financials

6.1.6.4       Pipeline

6.1.7          Johnson & Johnson

6.1.7.1       Overview

6.1.7.2       Diabetes Products

6.1.7.3       Financials

6.1.8          Medtronic

6.1.8.1       Overview

6.1.8.2       Diabetes Products

6.1.8.2.1          Paradigm 512/712 insulin pump

6.1.8.2.2          Paradigm 515/715 insulin pump

6.1.8.2.3          CGMS System Gold

6.1.8.3       Financials

6.1.8.4       Pipeline

6.1.9          Merck KgaA

6.1.9.1       Overview

6.1.9.2       Diabetes Product

6.1.9.3       Financials

6.1.10        Novartis

6.1.10.1     Overview

6.1.10.2     Diabetes Product

6.1.10.3     Financials

6.1.10.4     Pipeline

6.1.11        Novo Nordisk

6.1.11.1     Overview

6.1.11.2     Diabetes Products

6.1.11.2.1        Pharmaceuticals

6.1.11.3     Financials

6.1.11.4     Pipeline

6.1.12        Pfizer

6.1.12.1     Overview

6.1.12.2     Diabetes Products

6.1.12.3     Financials

6.1.12.4     Pipeline

6.1.13        Roche

6.1.13.1     Overview

6.1.13.2     Diabetes Products

6.1.13.2.1        Accutrend GC/GCT

6.1.13.3     Financials

6.1.13.4     Pipeline

6.1.14        Sanofi-Aventis

6.1.14.1     Overview

6.1.14.2     Diabetes Products

6.1.14.3     Financials

6.1.14.4     Pipeline

6.1.15        Takeda

6.1.15.1     Overview

6.1.15.2     Diabetes Products

6.1.15.3     Financials

6.1.15.4     Pipeline

6.1.15.4.1        TAK-559

6.1.15.4.2        TAK-654

6.2       Other Companies

6.2.1          77 Elektronica

6.2.2          Acon Laboratories

6.2.3          Activa

6.2.4          AdipoGenix

6.2.5          AgaMatrix

6.2.6          AiMedics Pty Ltd

6.2.7          Alkermes Inc.

6.2.8          Amylin

6.2.9          Animas Corp.

6.2.10        Antares Pharma

6.2.11        Apex Biotechnology Ltd

6.2.12        Aradigm

6.2.13        Arena Pharmaceuticals

6.2.14        B Braun

6.2.15        Belbiosens

6.2.16        Benitec Limited

6.2.17        Biocon

6.2.18        Bioject Medical Technologies Inc.

6.2.19        BioSafe Medical Technologies Inc

6.2.20        Biovitrum

6.2.21        Cell Robotics International, Inc

6.2.22        ChemGenex Pharmaceuticals Ltd

6.2.23        Dana Diabecare USA

6.2.24        Devgen NV

6.2.25        Dexcom Inc

6.2.26        Diabetes Technologies Inc.

6.2.27        Diagnostic Devices Inc.

6.2.28        Diosynth

6.2.29        EnGene

6.2.30        Equidyne Corporation

6.2.31        Eumed Biotechnology Co. Inc

6.2.32        FivePrime Therapeutics

6.2.33        FlexSite Diagnostics

6.2.34        Fluent Biomedical Inc

6.2.35        GlucoLight Corporation

6.2.36        Glucon Medical Ltd

6.2.37        Glucoplus Inc

6.2.38        GluMetrics LLC

6.2.39        Hemocue AB

6.2.40        Hitachi Ltd

6.2.41        HMD Biomedical

6.2.42        Home Diagnostics Inc

6.2.43        HypoGuard

6.2.44        Infratec Inc

6.2.45        InLight Solutions Inc

6.2.46        Integrity Applications Ltd

6.2.47        Kumetrix Inc

6.2.48        Laboratorios Beta

6.2.49        LifeTrac Systems Inc

6.2.50        Ligand Pharmaceuticals Inc

6.2.51        MannKind

6.2.52        Menarini

6.2.53        Metabolex

6.2.54        Metrika Inc.

6.2.55        Nektar Therapeutics

6.2.56        Nipro Diabetes Systems Inc

6.2.57        Owen Mumford

6.2.58        Palco Laboratories

6.2.59        Pelikan Technologies

6.2.60        Pindi Products

6.2.61        Polymer Technology Systems Inc

6.2.62        Provalis plc

6.2.63        QuestStar Medical Inc

6.2.64        Quotient Diagnostics Ltd

6.2.65        Rosch AG Medizintechnik

6.2.66        Sanwa Kagaku Kenkyusho Co. Ltd.

6.2.67        SenSys Medical

6.2.68        Laboratoires Servier

6.2.69        Sirna Therapeutics

6.2.70        Smiths Medical

6.2.71        Sontra Medical Corporation

6.2.72        SpectRx Inc

6.2.73        TaiDoc Technology Corporation

6.2.74        Terumo Medical Corporation

6.2.75        Theratechnologies Inc.

6.2.76        TolerRx Inc.

6.2.77        US Diagnostics Inc

6.2.78        Vaxine Pty Ltd.

6.2.79        VeraLight Inc.

6.2.80        Vivo Medical Inc.

6.2.81        Wockhardt Ltd

Appendix:  Company Addresses

 

 

List of Exhibits

Exhibit ES-1:  Total Diabetes Market, 2004

Exhibit ES-2:  Regional Segmentation of Diabetes Market

 

Exhibit 1.1:  Threshold Glucose Levels Indicative of Diabetes/Hyperglycemia (mmol/L)

Exhibit 1-2:  Main Brands and Types of Insulin

Exhibit 1-3:  Oral Diabetes Treatments

Exhibit 1-4:  Prevalence of Diabetes by Region (Age 20-79 Years)

Exhibit 1-5:  Differences in the Prevalence of Type 2 Diabetes Among Selected Ethnic Groups, 2003

Exhibit 1-6:  Prevalence of Diabetes in USA, 2003

Exhibit 1-7:  Incidence of Type 1 Diabetes in Western European countries (Cases per 100,000 Child Population, per Annum)

Exhibit 1-8:  Type 1 Diabetes Incidence Growth Rates in Selected European Countries

Exhibit 1-8:  Estimated Prevalence of Type 2 Diabetes in Western European Countries

 

Exhibit 2-1:  International Suppliers of Blood Lancets

Exhibit 2-2:  Blood Glucose Meters

Exhibit 2-3:  Research Projects in Glucose Monitoring

Exhibit 2-4:  Commercial Software Programs for Windows and Macintosh

 

Exhibit 3-1:  Major Brands of Insulin

Exhibit 3-2:  Manufacturers of Insulin Pens

Exhibit 3-3:  Manufacturers of Insulin Pups

Exhibit 3-4:  Sulfonylureas

Exhibit 3-5:  Oral Hypoglycemics

 

Exhibit 5-1:  Prevalence of Diabetes Mellitus, by Selected Country, 2003 and 2025 (Percent of Population Age 20-79)

Exhibit 5-2:  Global Diabetes Market 2004

Exhibit 5-3:  Relative Market Size of Major Regional Diabetes Markets; USA, Western Europe and Japan

Exhibit 5-4:  Glucose Monitors: Leading Companies 2004

Exhibit 5-5:  Market Shares, Insulin, Worldwide, 2004

Exhibit 5-6:  Market Shares, Insulin Syringes, Worldwide, 2004

Exhibit 5-7:  Market Shares, Insulin Pens, Worldwide, 2004

Exhibit 5-8:  Market Shares, Insulin Pumps, Worldwide, 2004

Exhibit 5-9:  Market Shares, Oral Antidiabetic Drugs, Worldwide, 2004

Exhibit 5-10:  Market for Insulin and Other Diabetes Medications, Belgium, 2003-2015

Exhibit 5-11:  Market for Glucose Meters, Belgium, 2003-2015

Exhibit 5-12:  Market for Insulin Pumps, Belgium, 2003-2015

Exhibit 5-13:  Market for Insulin and Other Diabetes Medications, Denmark, 2003-2015

Exhibit 5-14:  Market for Glucose Meters, Denmark, 2003-2015

Exhibit 5-15:  Market for Insulin and Other Diabetes Medications, France, 2003-2015

Exhibit 5-16:  Market for Glucose Meters, France, 2003-2015

Exhibit 5-17:  Market for Insulin Pumps, France, 2003-2015

Exhibit 5-18:  Market for Insulin and Other Diabetes Medications, Germany, 2003-2015

Exhibit 5-19:  Market for Glucose Meters, Germany, 2003-2015

Exhibit 5-20:  Market for Insulin Pumps, Germany, 2003-2015

Exhibit 5-21:  Market for Insulin and Other Diabetes Medications, Italy, 2003-2015

Exhibit 5-22:  Market for Glucose Meters, Italy, 2003-2015

Exhibit 5-23:  Market for Insulin Pumps, Italy, 2003-2015

Exhibit 5-24:  Market for Insulin and Other Diabetes Medications, Japan, 2003-2015

Exhibit 5-25:  Market for Glucose Meters, Japan, 2003-2015

Exhibit 5-26:  Market for Insulin Pumps, Japan, 2003-2015

Exhibit 5-27:  Market for Insulin and Other Diabetes Medications, Netherlands, 2003-2015

Exhibit 5-28:  Market for Glucose Meters, Netherlands, 2003-2015

Exhibit 5-29:  Market for Insulin Pumps, Netherlands, 2003-2015

Exhibit 5-30:  Market for Insulin and Other Diabetes Medications, Norway, 2003-2015

Exhibit 5-31:  Market for Glucose Meters, Norway, 2003-2015

Exhibit 5-32:  Market for Insulin Pumps, Norway, 2003-2015

Exhibit 5-33:  Market for Insulin and Other Diabetes Medications, Spain, 2003-2015

Exhibit 5-34:  Market for Glucose Meters, Spain, 2003-2015

Exhibit 5-35:  Market for Insulin Pumps, Spain, 2003-2015

Exhibit 5-36:  Market for Insulin and Other Diabetes Medications, Sweden, 2003-2015

Exhibit 5-37:  Market for Glucose Meters, Sweden, 2003-2015

Exhibit 5-38:  Market for Insulin Pumps, Sweden, 2003-2015

Exhibit 5-39:  Market for Insulin and Other Diabetes Medications, United Kingdom, 2003-2015

Exhibit 5-40:  Market for Glucose Meters, United Kingdom, 2003-2015

Exhibit 5-41:  Market for Insulin Pumps, United Kingdom, 2003-2015

Exhibit 5-42:  Market for Insulin and Other Diabetes Medications, United States, 2003-2015

Exhibit 5-43:  Market for Glucose Meters, United States, 2003-2015

Exhibit 5-44:  Market for Insulin Pumps, United States, 2003-2015

 

Exhibit 6-1:  Abbott Laboratories Financial Data, 2004

Exhibit 6-2:  Bayer Group Financials, 2004

Exhibit 6-3:  Becton Dickinson Financials, 2004

Exhibit 6-4:  Bristol-Myers Squibb Financials, 2004

Exhibit 6-5:  Eli Lilly Financials, 2004

Exhibit 6-6:  Glaxo SmithKline Financials, 2004

Exhibit 6-7:  Glaxo SmithKline Diabetes Products in Research Pipeline

Exhibit 6-8:  J&J Medical Devices and Diagnostics Financials, 2004

Exhibit 6-9:  Medtronic Financials, 2004

Exhibit 6-10:  Merck KGaA Financials, 2004

Exhibit 6-11:  Novartis Financials, 2004

Exhibit 6-12:  Novo Nordisk Financials, 2004

Exhibit 6-13:  Pfizer leading products

Exhibit 6-14:  Pfizer Financials, 2004

Exhibit 6-15:  Roche Financials, 2004

Exhibit 6-16:  Sanofi Aventis, Leading Products 2004

Exhibit 6-17:  Sanofi-Aventis Financials, 2004

Exhibit 6-18:  Takeda Leading Products

Exhibit 6-19:  Takeda Financials, 2005

 


Report #D500 has been updated in the 2010 report #D510:  
"Products, Technologies, Markets and Opportunities in Diabetes Management Worldwide, 2009-2018"
Click for details

 

 

Report #D500: Products, Technologies, Markets and Opportunities in Diabetes Management Worldwide, 2005-2015
 

Price:  $1,250 for print or PDF; $1,450 for both.

 

Order report online    .

 

Methodology.
MedMarket Diligence Reports are produced through primary and secondary research. Data is gathered from published sources on products and technologies on the market and under development.  Clinicians and industry representatives are interviewed for their knowledge and insights on product development, market development, clinical practice and trends associated with the evolving use of technologies. Secondary data is used to corroborate and support assessments and projections.  Reports are written and researched by industry insiders, whose familiarity with the companies, industry dynamics and other marketplace specifics facilitate the research process and ensure high quality and thorough reports.

 

 

 

Contact: Patrick Driscoll, (949) 891-1753.  (patrick AT mediligence DOT com)

Copyright © 2006 MedMarket Diligence, LLC. All rights reserved.
Revised: 02/16/11

Our clients


Or call
+1.949.891.1753
+1.949.415.2609 fax

advanced medical technologies blog

Medtech Startups

Medtech financing archives

 

 
Follow us on Twitter
Follow medmarket

MedMarket Diligence Reports Coverage

 

Medtech Startups
Online database of recent medtech startups

 

 

Contact Us